Merck

First Ebola vaccine doses arrive in Congo amid deadliest outbreak

A new Ebola vaccine targeting the Bundibugyo strain could be ready by the end of 2026, the head of the world's leading authority on vaccines has said, as the fastest-growing Ebola outbreak in history continues to devastate the Democratic Republic…

Moderna shares surge after mRNA cancer vaccine clears Phase 3 trial

Moderna shares soared as much as 100% on Wednesday after the company and partner Merck announced that their personalized mRNA cancer vaccine met both primary goals in a pivotal late-stage melanoma trial — the first positive Phase 3 result ever…

Merck, Moderna mRNA cancer vaccine succeeds in Phase 3 trial

Merck and Moderna announced Wednesday that their personalized mRNA cancer vaccine succeeded in a Phase 3 clinical trial, marking the first late-stage positive readout for an individualized neoantigen therapy and for any mRNA-based cancer treatment.

CEPI funds first Bundibugyo Ebola vaccine as Congo outbreak doubles every 20 days

Senior United Nations officials called Wednesday for a three- to five-fold increase in the international response to the Ebola outbreak in eastern Democratic Republic of Congo, warning that the epidemic is doubling in size every 20 days and outpacing containment…

Gilead, Merck once-weekly HIV pill succeeds in Phase 3

Gilead Sciences and Merck announced on Sunday that their investigational once-weekly combination pill of islatravir and lenacapavir met its primary efficacy endpoint in two Phase 3 trials, marking a potential milestone in HIV treatment as the first long-acting oral therapy…